INMB
INmune Bio, Inc.
There isn't enough reported data to score INMB yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
INMB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
INMB's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
INMB PE Valuation
INMB has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
INMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INMB's revenue to decline, with its earnings and profitability holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
INMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.56 | +$1.56 |
| Q2 2026 | -$0.63 | +$1.85 |
| Q1 2026 | -$1.63 | +$0.30 |
| Q4 2025 | -$1.86 | +$0.25 |
| Q3 2025 | -$2.12 | +$0.06 |
| Q2 2025 | -$2.48 | -$0.42 |
| Q1 2025 | -$1.93 | -$0.01 |
| Q4 2024 | -$2.11 | -$0.44 |
INMB is still losing money, but far less than before: $0.56 per share over the past year, against $2.48 at its worst in mid-2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over INMB on earnings quality, reporting a profit while its opponent remains loss making.
INMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2025 | $50K | +257% |
| Q1 2024 | $14K | -63% |
| Q4 2023 | $28K | -71% |
| Q3 2023 | $43K | -56% |
| Q2 2023 | $46K | +188% |
| Q1 2023 | $38K | -77% |
| Q4 2022 | $97K | -40% |
| Q3 2022 | $98K | +600% |
INMB's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -19810% | +58883 points |
| Q1 2024 | -78693% | -61790 points |
| Q4 2023 | -29925% | -24109 points |
| Q3 2023 | -19833% | -12238 points |
| Q2 2023 | -13937% | +25988 points |
| Q1 2023 | -16903% | -12928 points |
| Q4 2022 | -5816% | -277 points |
| Q3 2022 | -7595% | +56841 points |
INMB's operating margin was −19810% last quarter, down 5873 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
INMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | +$2.2M |
| Q1 2026 | -$3.4M | +$3.4M |
| Q4 2025 | -$3.1M | +$7.9M |
| Q3 2025 | -$5.6M | +$1.4M |
| Q1 2025 | -$6.8M | +$652K |
| Q4 2024 | -$11M | -$7.6M |
| Q3 2024 | -$7M | -$2.7M |
| Q2 2024 | -$7.9M | -$4.7M |
INMB has burned cash in almost every quarter: −$13M over the past year, against −$30M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over INMB on cash generation, producing positive trailing cash flow while its opponent burns cash.
INMB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +1.1M shares |
| 1 year | +4.6% | +1.2M shares |
| 3 years | +54% | +9.8M shares |
| 5 years | +60% | +10.5M shares |
| Available history | +171% | +17.5M shares |
INMB has 28M diluted shares, up 4.6% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over INMB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
INMB Net Leverage
INMB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
INMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 3.7 | Oversold |
INMB's weekly RSI is 32 (neutral) and its Stochastic is 4 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
INMB PE vs Healthcare Sector
INMB has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 33% below |
| 20 week MA | $1.87 | 44% below |
| 50 week MA | $1.63 | 36% below |
| 100 week MA | $3.33 | 68% below |
| 200 week MA | $5.90 | 82% below |
INMB is in a downtrend: it's below all five of its weekly moving averages, and 82% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over INMB on trend strength, trading above more of its moving averages.
INMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.35 | $12.8 | +138% |
| 2021 | $12.8 | $10.9 | -15% |
| 2022 | $10.9 | $7.03 | -35% |
| 2023 | $7.03 | $11.3 | +60% |
| 2024 | $11.3 | $4.65 | -59% |
| 2025 | $4.65 | $1.73 | -63% |
| 2026 YTD | $1.73 | $1.05 | -39% |
INMB's yearly returns have swung widely, from +138% in 2020 to −63% in 2025. It's down 39% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over INMB on returns for 2026, with the stronger performance.